Tolcapone and hepatotoxic effects

Archives of Neurology

Volumn 57, Issue 2, 2000, Pages 263-267

  Olanow, C Warren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPA; BENSERAZIDE; CATECHOL METHYLTRANSFERASE; LEVODOPA; TOLCAPONE;

ADULT; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL;

EID: 0033977448     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.2.263     Document Type: Article

References (12)

1. Kaakola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selctive inhibitors of catechol-0-methyl transferase. Gen Pharmacol. 199-4; 25:813-824.
2. Dingemase J, Jorga K, Zurger G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J din Phamacol. 1995:40:253-262.
3. Dingemase J, Jorga K, Zürcher G, et al. Multiple-dose clinical pharmacology of the catechol-0-methyl-transferase inhibitor tolcapone in elderly subjects. EurJ Clin Pharmacol. 1996:50:47-55.
4. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebocontrolled trial. Neurology. 1997:48:81-87.
5. Bass H, Beiske AG, Ghika J, et al. COMT inhibition with tolcapone reduces the "wearing off phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997:63:421-428.
6. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing off" phenomenon: a double-blind, placebo-controlled, multi-center trial. Neurology. 1997:49:1066-1071.
7. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology. 1997:99:665-671.
8. Dupont E, Burgunder JM, Findley LJ, et al. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. MovDisord. 1997; 12:928-934.
9. Tasmar (tolcapone) tablets [prescribing information]. Nutley, NJ: Roche Laboratories Inc; November 1998.
10. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet. 1998:352:958.
11. New Warnings for Parkinson's Drug Tasmar. Rockville, Md: Food and Drug Administration; November 16,1998. Talk Paper T98-81.
12. Ellison RH. Dear health professional letter regarding appropriate use of Tasmar. Nutley, NJ: Roche Laboratories Inc; November 16,1998.